Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy suc...
Gespeichert in:
| Veröffentlicht in: | Trends in immunology 2020-10, Vol.41 (10), p.948 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | 948 |
| container_title | Trends in immunology |
| container_volume | 41 |
| creator | Kim, Hye-Jung Cantor, Harvey Cosmopoulos, Kat |
| description | Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy such as immune checkpoint blockade (ICB). Emerging evidence shows that targeting epigenetic elements that promote tumor progression and inhibit immune cell activity can enhance antitumor immunity by reshaping the tumor microenvironment (TME). Here, we review the pleiotropic functions in tumor and immune cells of enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), with a focus on EZH2 inhibition as a potentially promising approach to enhance current immunotherapies and improve patient outcomes for certain cancers. |
| doi_str_mv | 10.1016/j.it.2020.08.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2445951353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2445951353</sourcerecordid><originalsourceid>FETCH-LOGICAL-p206t-c8599b6f469fd7594f5c884fc162fe8680a7ebb09de2e68abc562887110c7d2d3</originalsourceid><addsrcrecordid>eNo9j0tLw0AYRQdRbK3uXcmA68RvJvNcalttoFAQ3bgJk8nETtpMYh4F_70Fq6t7F4dzuQjdEogJEPFQxX6IKVCIQcVA4AxNCZMkYlqR8_8OYoKu-r4CIFxKeYkmCdVSSAZTtNgcXGeb2odPnNb1GByeb53dtY0PA37aN3ZnCodfXe_7wQTr8MEbvPxYUZyGrc_94JtwjS5Ks-_dzSln6P15-TZfRevNSzp_XEctBTFEVnGtc1EyoctCcs1KbpVipSWClk4JBUa6PAddOOqEMrnlgiolCQErC1okM3T_62275mt0_ZBVzdiF42RGGeOak4QnR-ruRI157Yqs7Xxtuu_s73TyAzlYWEY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2445951353</pqid></control><display><type>article</type><title>Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kim, Hye-Jung ; Cantor, Harvey ; Cosmopoulos, Kat</creator><creatorcontrib>Kim, Hye-Jung ; Cantor, Harvey ; Cosmopoulos, Kat</creatorcontrib><description>Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy such as immune checkpoint blockade (ICB). Emerging evidence shows that targeting epigenetic elements that promote tumor progression and inhibit immune cell activity can enhance antitumor immunity by reshaping the tumor microenvironment (TME). Here, we review the pleiotropic functions in tumor and immune cells of enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), with a focus on EZH2 inhibition as a potentially promising approach to enhance current immunotherapies and improve patient outcomes for certain cancers.</description><identifier>ISSN: 1471-4906</identifier><identifier>EISSN: 1471-4981</identifier><identifier>DOI: 10.1016/j.it.2020.08.010</identifier><identifier>PMID: 32976740</identifier><language>eng</language><publisher>England: Elsevier Limited</publisher><subject>Anticancer properties ; Antigens ; Apoptosis ; Cancer ; Cancer immunotherapy ; Cell adhesion & migration ; Cyclin-dependent kinases ; Cytokines ; DNA methylation ; Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors ; Epigenetics ; Fibroblasts ; Gene expression ; Genotype & phenotype ; Homology ; Humans ; Immune checkpoint ; Immune Checkpoint Inhibitors - therapeutic use ; Immune system ; Immunotherapy ; Infections ; Kinases ; Lymphocytes ; Lymphoma ; Melanoma ; Neoplasms - drug therapy ; Polycomb group proteins ; T cell receptors ; Tumor Microenvironment - immunology ; Tumors</subject><ispartof>Trends in immunology, 2020-10, Vol.41 (10), p.948</ispartof><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32976740$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Hye-Jung</creatorcontrib><creatorcontrib>Cantor, Harvey</creatorcontrib><creatorcontrib>Cosmopoulos, Kat</creatorcontrib><title>Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition</title><title>Trends in immunology</title><addtitle>Trends Immunol</addtitle><description>Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy such as immune checkpoint blockade (ICB). Emerging evidence shows that targeting epigenetic elements that promote tumor progression and inhibit immune cell activity can enhance antitumor immunity by reshaping the tumor microenvironment (TME). Here, we review the pleiotropic functions in tumor and immune cells of enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), with a focus on EZH2 inhibition as a potentially promising approach to enhance current immunotherapies and improve patient outcomes for certain cancers.</description><subject>Anticancer properties</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cell adhesion & migration</subject><subject>Cyclin-dependent kinases</subject><subject>Cytokines</subject><subject>DNA methylation</subject><subject>Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors</subject><subject>Epigenetics</subject><subject>Fibroblasts</subject><subject>Gene expression</subject><subject>Genotype & phenotype</subject><subject>Homology</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Kinases</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Melanoma</subject><subject>Neoplasms - drug therapy</subject><subject>Polycomb group proteins</subject><subject>T cell receptors</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><issn>1471-4906</issn><issn>1471-4981</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j0tLw0AYRQdRbK3uXcmA68RvJvNcalttoFAQ3bgJk8nETtpMYh4F_70Fq6t7F4dzuQjdEogJEPFQxX6IKVCIQcVA4AxNCZMkYlqR8_8OYoKu-r4CIFxKeYkmCdVSSAZTtNgcXGeb2odPnNb1GByeb53dtY0PA37aN3ZnCodfXe_7wQTr8MEbvPxYUZyGrc_94JtwjS5Ks-_dzSln6P15-TZfRevNSzp_XEctBTFEVnGtc1EyoctCcs1KbpVipSWClk4JBUa6PAddOOqEMrnlgiolCQErC1okM3T_62275mt0_ZBVzdiF42RGGeOak4QnR-ruRI157Yqs7Xxtuu_s73TyAzlYWEY</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Kim, Hye-Jung</creator><creator>Cantor, Harvey</creator><creator>Cosmopoulos, Kat</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>202010</creationdate><title>Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition</title><author>Kim, Hye-Jung ; Cantor, Harvey ; Cosmopoulos, Kat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p206t-c8599b6f469fd7594f5c884fc162fe8680a7ebb09de2e68abc562887110c7d2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anticancer properties</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cell adhesion & migration</topic><topic>Cyclin-dependent kinases</topic><topic>Cytokines</topic><topic>DNA methylation</topic><topic>Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors</topic><topic>Epigenetics</topic><topic>Fibroblasts</topic><topic>Gene expression</topic><topic>Genotype & phenotype</topic><topic>Homology</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Kinases</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Melanoma</topic><topic>Neoplasms - drug therapy</topic><topic>Polycomb group proteins</topic><topic>T cell receptors</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Hye-Jung</creatorcontrib><creatorcontrib>Cantor, Harvey</creatorcontrib><creatorcontrib>Cosmopoulos, Kat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Trends in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Hye-Jung</au><au>Cantor, Harvey</au><au>Cosmopoulos, Kat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition</atitle><jtitle>Trends in immunology</jtitle><addtitle>Trends Immunol</addtitle><date>2020-10</date><risdate>2020</risdate><volume>41</volume><issue>10</issue><spage>948</spage><pages>948-</pages><issn>1471-4906</issn><eissn>1471-4981</eissn><abstract>Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy such as immune checkpoint blockade (ICB). Emerging evidence shows that targeting epigenetic elements that promote tumor progression and inhibit immune cell activity can enhance antitumor immunity by reshaping the tumor microenvironment (TME). Here, we review the pleiotropic functions in tumor and immune cells of enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), with a focus on EZH2 inhibition as a potentially promising approach to enhance current immunotherapies and improve patient outcomes for certain cancers.</abstract><cop>England</cop><pub>Elsevier Limited</pub><pmid>32976740</pmid><doi>10.1016/j.it.2020.08.010</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-4906 |
| ispartof | Trends in immunology, 2020-10, Vol.41 (10), p.948 |
| issn | 1471-4906 1471-4981 |
| language | eng |
| recordid | cdi_proquest_journals_2445951353 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anticancer properties Antigens Apoptosis Cancer Cancer immunotherapy Cell adhesion & migration Cyclin-dependent kinases Cytokines DNA methylation Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Epigenetics Fibroblasts Gene expression Genotype & phenotype Homology Humans Immune checkpoint Immune Checkpoint Inhibitors - therapeutic use Immune system Immunotherapy Infections Kinases Lymphocytes Lymphoma Melanoma Neoplasms - drug therapy Polycomb group proteins T cell receptors Tumor Microenvironment - immunology Tumors |
| title | Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T19%3A52%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overcoming%20Immune%20Checkpoint%20Blockade%20Resistance%20via%20EZH2%20Inhibition&rft.jtitle=Trends%20in%20immunology&rft.au=Kim,%20Hye-Jung&rft.date=2020-10&rft.volume=41&rft.issue=10&rft.spage=948&rft.pages=948-&rft.issn=1471-4906&rft.eissn=1471-4981&rft_id=info:doi/10.1016/j.it.2020.08.010&rft_dat=%3Cproquest_pubme%3E2445951353%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2445951353&rft_id=info:pmid/32976740&rfr_iscdi=true |